Recent Price Movement and Market Context
On 10 Mar 2026, Indo US Bio-Tech Ltd recorded an intraday low of Rs.97.65, down 4.59% from its previous close, while the intraday high was Rs.104.85, representing a 2.44% gain during the session. The stock has been on a three-day losing streak, cumulatively falling by 26.35% over this period. This decline contrasts with the broader market, where the Sensex, despite a volatile session, ended with a modest gain of 0.45%, trading at 77,912.67. However, the Sensex itself has been under pressure, falling 5.92% over the past three weeks.
Indo US Bio-Tech’s performance today also lagged its sector, Other Agricultural Products, by 0.67%. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained bearish momentum. This technical positioning underscores the challenges the stock faces in regaining upward momentum.
Long-Term and Recent Performance Metrics
Over the past year, Indo US Bio-Tech Ltd has delivered a total return of -44.40%, significantly underperforming the Sensex’s 5.09% gain during the same period. The stock’s 52-week high was Rs.205.10, highlighting the extent of the decline from its peak. This underperformance extends beyond the last year, with the stock lagging the BSE500 index over the last three years, one year, and three months.
Financially, the company’s operating profit has grown at an annualised rate of 19.07% over the last five years, which is considered modest within its industry. However, recent quarterly results have shown a downturn. Net sales for the latest quarter stood at Rs.22.80 crores, down 23.1% compared to the previous four-quarter average. Profit after tax (PAT) for the latest six months declined by 31.46%, while PBDIT for the quarter was at a low of Rs.4.15 crores. These figures reflect a contraction in near-term profitability and revenue generation.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Valuation and Efficiency Indicators
Despite the recent price weakness, Indo US Bio-Tech Ltd exhibits some positive financial characteristics. The company maintains a high return on capital employed (ROCE) of 27.98%, indicating efficient use of capital in generating profits. Its debt servicing capability is strong, with a low Debt to EBITDA ratio of 0.91 times, suggesting manageable leverage levels.
Valuation metrics also point to an attractive entry point relative to peers. The company’s ROCE of 16.4% combined with an enterprise value to capital employed ratio of 2 positions it favourably in terms of valuation. The stock is trading at a discount compared to the average historical valuations of its sector peers. Over the past year, while the stock price has declined by 44.40%, the company’s profits have increased by 13.2%, resulting in a PEG ratio of 1.1, which is considered reasonable.
Technical Analysis Overview
Technical indicators present a mixed picture. On a weekly basis, the MACD and KST indicators are mildly bullish, while monthly readings for both are bearish. The Relative Strength Index (RSI) shows no clear signal weekly but is bullish monthly. Bollinger Bands indicate bearish trends on both weekly and monthly charts. Daily moving averages remain bearish, and Dow Theory assessments are mildly bearish on both weekly and monthly timeframes. On-balance volume (OBV) shows no definitive trend on either timeframe.
Shareholding and Market Grade
The majority of shares are held by promoters, reflecting concentrated ownership. The company’s Mojo Score stands at 38.0, with a current Mojo Grade of Sell, downgraded from Hold on 19 Jan 2026. The market capitalisation grade is 4, indicating a smaller market cap relative to larger peers.
Indo US Bio-Tech Ltd or something better? Our SwitchER feature analyzes this micro-cap Other Agricultural Products stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Environment
Indo US Bio-Tech operates within the Other Agricultural Products sector, which has seen mixed performance amid broader market volatility. The Sensex’s recent three-week decline of 5.92% and its current trading below the 50-day moving average reflect a cautious market environment. Mega-cap stocks have led the market gains recently, while smaller and mid-cap stocks, including Indo US Bio-Tech, have faced greater pressure.
Summary of Key Financial and Market Data
The stock’s new 52-week low of Rs.97.65 contrasts sharply with its 52-week high of Rs.205.10, underscoring the significant price correction. The company’s quarterly net sales of Rs.22.80 crores represent a 23.1% decline from the previous four-quarter average, while PAT for the latest six months fell by 31.46%. PBDIT for the quarter was Rs.4.15 crores, the lowest recorded in recent periods.
Despite these challenges, Indo US Bio-Tech maintains strong management efficiency, a robust ROCE of 27.98%, and a low Debt to EBITDA ratio of 0.91 times. The valuation metrics suggest the stock is trading at a discount relative to peers, with a PEG ratio of 1.1 indicating moderate valuation relative to earnings growth.
Technically, the stock remains in a bearish phase, trading below all major moving averages and showing mixed signals across various momentum indicators. The downgrade to a Sell grade by MarketsMOJO on 19 Jan 2026 reflects these combined factors.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
